Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XTL BiopharmaceuticalsXTLB -0.54%26 3-Year EBITDA Growth Rate is 34.10% as of Dec. 2025, which is 130% above its 10-year median of 14.80. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, XTL Biopharmaceuticals ranks better than 72.24% on this metric.
During the past 12 months, XTL Biopharmaceuticals's average EBITDA Per Share Growth Rate was -200.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of XTL Biopharmaceuticals was 74.20% per year. The lowest was -110.80% per year. And the median was 14.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
XTL Biopharmaceuticals 3-Year EBITDA Growth Rate Related Terms
XTLB vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.10% mean?
XTL Biopharmaceuticals (XTLB) has a 3-Year EBITDA Growth Rate of 34.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for XTL Biopharmaceuticals and its competitors. This is 130% above median its historical median of 14.80. According to the industry distribution chart, XTL Biopharmaceuticals ranks #314 out of 1131 companies in the Biotechnology industry, placing it in the top 27.8%.
Is XTL Biopharmaceuticals' 3-Year EBITDA Growth Rate too high?
XTL Biopharmaceuticals' current 3-Year EBITDA Growth Rate of 34.10% is 130% above median its 10-year median of 14.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. XTL Biopharmaceuticals' value of 34.10% is 128.9% above this industry median. Based on the distribution chart, XTL Biopharmaceuticals ranks #314 out of 1131 companies in the Biotechnology industry, which is above the industry midpoint. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #314 out of 1131 companies for 3-Year EBITDA Growth Rate. This puts XTL Biopharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. XTL Biopharmaceuticals' value of 34.10% is 128.9% above this benchmark. While the company's 10-year median is 14.80 vs. the industry median of 14.90, XTL Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XTL Biopharmaceuticals's current 3-Year EBITDA Growth Rate of 34.10% is 128.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for XTL Biopharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current 3-Year EBITDA Growth Rate is 34.10%, which is 130% above median its own 10-year median of 14.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current 3-Year EBITDA Growth Rate of 34.10%. The current 3-Year EBITDA Growth Rate is 34.10%, which is 130% above median its 10-year median of 14.80 and 128.9% above the Biotechnology industry median of 14.90. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current 3-Year EBITDA Growth Rate is 34.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score
Get the complete analysis for XTLB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
